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Abstract 
Seven P2X ion channel nucleotide receptor subtypes have been cloned and characterised. 
P2X7 receptors (P2X7R) are unusual in that there are extra amino acids in the intracellular C 
terminus. Low concentrations of ATP open cation channels sometimes leading to cell 
proliferation, whereas high concentrations of ATP open large pores that release inflammatory 
cytokines and can lead to apoptotic cell death. Since many diseases involve inflammation and 
immune responses, and the P2X7R regulates inflammation, there has been recent interest in 
the pathophysiological roles of P2X7R and the potential of P2X7R antagonists to treat a 
variety of diseases. These include neurodegenerative diseases, psychiatric disorders, epilepsy 
and a number of diseases of peripheral organs, including the cardiovascular, airways, kidney, 
liver, bladder, skin and musculoskeletal. The potential of P2X7R drugs to treat tumour 
progression is discussed.  
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Introduction 
P2X receptors are a family of ionotropic ATP-gated receptors, they are cation-selective 
channels, equally permeable to Na+ and K
+ and with significant Ca2+ permeability. Seven 
mammalian subunits have been cloned to date (P2X1-7) that form either functional homo- 
and heterotrimers. When 3 molecules of ATP bind to a P2X receptor, the pore opens within 
milliseconds, allowing the cations to flow. P2X7 receptors (P2X7R) differ in that they have 
extra amino acids in the intracellular C terminus and are bi-functional, the binding of ATP 
within milliseconds induces the opening of a channel selective for small cations, and within 
seconds a larger pore opens, which allows permeation by molecules with a mass of up to 900 
Da (leading to release of inflammatory cytokines and apoptosis) (see [1, 2]). 
 An important review was published about the development of P2X7R antagonists for 
anti-inflammatory therapy, including therapeutic potential and recent discoveries [3]. More 
recent reviews about P2X ion channel receptors and inflammation [1] and the P2X7R as a 
therapeutic target [4] have been published. This review is focused largely on the recent 
interest since 2014 about the involvement of P2X7R in inflammation and tumour 
progression. 
 
P2X7R and inflammation 
The P2X7R has been implicated in the regulation of inflammation [5] and virtually all 
immune cell types (both of innate and adaptive immunity, including lymphocytes, 
macrophages, monocytes, neutrophils, basophils, dendritic cells, eosinophils and mast cells) 
express P2X7R [6]. They therefore represent significant therapeutic potential. A review was 
published in 2015 that discussed those P2X7R antagonists that exhibited promising 
therapeutic potential for the treatment of inflammatory diseases, pain and cancer [7]. Other 
reviews have been published that highlight the involvement of P2X7R in neuroinflammation 
and how medicinal chemists are working to identify centrally penetrant antagonists [8, 9]. For 
instance, GSK1482160 is a potent P2X7R antagonist with blood brain barrier penetration, 
which has the ability to be radiolabelled with 11C. This allows it to be potentially useful as a 
biomarker of neuroinflammation [10], since P2X7R may mediate the neuroinflammation and 
cognitive impairment that can result following surgery [11]. Another review explored the role 
of P2X7R in fibrosis, the pathological outcome of most chronic inflammatory diseases [12]. 
 Activation of P2X7R is associated with immune responses, including allergic 
inflammation [13]. ATP released from damaged or infected cells causes inflammation by 
activation of P2X7R and subsequent release of inflammatory cytokines, such as interleukin 
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(IL)-1β, thereby acting as a danger signal by activating P2X7R on immune cells to increase 
immune responses [14]. An example of this is seen in enteric epithelial cells in conditions of 
inflammation of the gut (see [1]; Figure 1). Pulmonary neutrophils are the inflammatory cells 
that are initially recruited during lung injury. Antagonism of the P2X7R with 
AZ106006120, or knockout (KO) of the receptor, reduced neutrophil infiltration and pro-
inflammatory cytokine levels in a mouse model of acute lung injury [15]. Human and murine 
neutrophils express functional P2X7R, which mediate NLRP3 inflammasome-dependent IL-
1 secretion [16]. Nanobodies are small, single-domain antibody fragments and a mouse 
nanobody, 13A7, was shown to block gating of the P2X7R channel on T cells and 
macrophages in vivo and is proposed as a new drug candidate for inflammatory disorders 
[17].  
 
P2X7R in inflammation, infection and immunity 
Extracellular ATP is an endogenous danger signal that activates inflammatory responses in 
immune cells. The role of P2X7R in infectious inflammatory diseases has been reviewed [8, 
18, 19]. P2X7R are needed for the development of the inflammatory response associated with 
sepsis in mice [20, 21] and Brilliant Blue G (BBG; a selective antagonist for mouse P2X7R 
that is blood brain barrier permeable and safe) was shown to ameliorate sepsis-induced brain 
damage [22]. Also in mice, P2X7R downstream of caspase-11 play a critical role for 
pyroptosis and susceptibility to sepsis induced by the non-canonical inflammasome [23]. 
 The use of P2X7R agonists in conjunction with low molecular weight anti-bacterial 
medicines has been proposed for the treatment of multi-drug-resistant tuberculosis [24]. 
P2X7R antagonists are potential tools for the treatment of Clostridium perfringens type C 
[25] and Porphyromonas gingivalis [26] infections. P2X7 activation was shown to be 
protective during severe Escherichia coli infection in mice [27]. Similarly, ATP release from 
infected macrophages and subsequent activation of P2X7R are critical for IL-1-dependent 
host protection from Bacillus anthracis [28]. The role of P2X7R and ectonucleotidases in 
infectious inflammatory diseases has been reviewed [19]. 
 Evidence was presented to show that mouse P2X7R are involved in containing the 
parasitic protozoan Toxoplasma gondii spread in vivo, by stimulating inflammation [29]. The 
dysfunction of P2X7R is likely to contribute to morbidity due to human schistosomiasis, a 
chronic inflammatory disease [30]. P2X7R-deficient mice were more susceptible to 
Fig 1 
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Leishmania amazonensis infection than wild type (WT) mice, suggesting that P2X7R play a 
key role in parasite control by regulating T effector cells and inflammation [31].  
 P2X7R activation regulates inflammatory responses during acute viral infection in 
mice [32]. Upregulated expression of P2X7R on peripheral blood mononuclear cells provides 
antiviral immunity in patients against hepatitis C virus [33], while activation of P2X7R 
participates in the exacerbated immune response that occurs during influenza virus infection 
in mice [34]. P2X7R play a role in control of Dengue virus-2 infection and KN62 appeared to 
have antiviral and anti-inflammatory actions in infected human monocytes [35]. Purinergic 
receptors, particularly P2X7, have been identified as key mediators of human 
immunodeficiency virus-1 (HIV-1) infection and inflammation [36] and ATP induces rapid 
release of HIV-1 from virus containing compartments of human macrophages [37]. In HIV-1 
infection, abnormalities in neuron-glia interactions result in neuronal damage. HIV-1 Tat-
induces neuronal apoptosis and augments the expression of P2X7R in astrocytes. Oxidised 
ATP (OxATP), A-438079 and BBG attenuated Tat-mediated neurotoxicity and may be novel 
tools for therapeutic management of neuroAIDS [38].  
 A valuable review discusses the role of purinergic signalling in autoimmunity and 
highlights a role for P2X7R in systemic lupus erythematosus [39]. P2X7R activation deleted 
intestinal T cells by apoptosis and suppressed T-cell-induced colitis in mice [40]. P2X7R are 
expressed on peripheral lymphocytes and may influence the immune profile from patients 
with the indeterminate form of Chagas disease [41].  
 
P2X7R and inflammatory neuropathic pain 
The earlier literature about the involvement of P2X7R in neuropathic pain has been reviewed 
[42].   
 Genetically determined P2X7R pore formation was shown to regulate variability in 
chronic pain sensitivity [43]. P2X7R activation by endogenous ATP contributes to the 
development of inflammatory hyperalgesia. Removal of the P2X7R gene or P2X7R 
antagonists, such as BBGBrilliant Blue G (BBG; a selective antagonist for mouse P2X7R that 
is blood brain barrier permeable and safe)  and oxidised ATP (oxATP), abolished chronic 
inflammatory and neuropathic pain in animal models (see review by Alves et al. [44]). 
Inflammatory pain that occurs in burn patients following dressing changes was relieved by 
puerarin treatment, which was claimed to act by decreasing the expression levels of P2X7R 
mRNA and protein in peripheral blood mononuclear cells [45]. P2X7R activation in vivo was 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6 
 
involved in the development of central sensitization in an acute inflammatory pain animal 
model (see [1]). 
 P2X7R antagonists were shown to have analgesic activity in a rat model of 
neuropathic pain. P2X7R expressed by microglia mediate neuropathic pain, which is reduced 
by antagonists, such as A-740003 and A-438079 (see [46]). Central nervous system (CNS)-
penetrant P2X7R antagonists may be beneficial for the treatment of persistent pain by 
targeting microglia. Resveratrol was shown to be neuroprotective against neuropathic pain 
mediated by the P2X7R expressed on satellite glial cells of the dorsal root ganglia (DRG) 
[47]. 
  
P2X7R and tumour progression 
A review covering the early literature about the involvement of purinergic signalling and 
cancer, including discussion about the roles of the P2X7R in a variety of tumours, is available 
[48].  
 The P2X7R is are a key mediator of inflammation and cancer invasion/metastasis and 
P2X7R antagonists are potential antimetastatic agents [49]. A feature of some cancer cells is 
the high level of expression of P2X7R, which, depending on the tumour type, can mediate 
either proliferation or cell death (see [50]). Thus, P2X7R activation may have effects on anti-
tumour immunity that are opposed to a direct effect on tumour growth. It was also pointed 
out in this review that there is increased release of ATP, promoting cancer cell migration and 
metastasis. High levels of extracellular ATP accumulate in tumour interstitium and high ATP 
doses inhibit migration of endothelial cells from human breast carcinoma, via the activation 
of P2X7R [51]. Human pancreatic duct adenocarcinoma cells in vitro express high levels of 
P2X7R protein and AZ10606120 inhibited cell proliferation [52]. ATP activation of P2X7R 
triggers immunogenic signalling, which converts dying cancer cells into an effective 
anticancer vaccine [53]. P2X7R activation is linked to elevated expression of inflammation 
promoting factors, tumour cell migration, increase in [Ca2+]i and membrane depolarization in 
malignant gliomas (see [54]; Figure 2). Evidence has been presented to suggest that P2X7R 
antagonists are promising therapeutic tools for the treatment of osteosarcoma [55]. Growth of 
experimental tumours is strongly inhibited by P2X7R antagonism of both cancer and immune 
cells (see [56]). A non-functional P2X7R, nfP2X7R, is expressed on cancer cells and has 
been proposed as a novel therapeutic target for human cancer [57, 58]. A phase I clinical trial 
has recently demonstrated that nfP2X7R-targeted antibodies were a novel, safe and tolerable 
Fig 2 
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topical therapy for basal cell carcinoma [59]. P2X7R activation induces apoptosis in acute 
myeloid leukaemia cells, but not in normal hematopoietic stem cells [60].  
 ACN human neuroblastoma cells express P2X7R, which is a regulator of its growth 
and angiogenesis, and AZ10606120 and A-740003 reduced ACN-derived tumour growth in 
nude mice so P2X7R may be a novel therapeutic target for treatment of neuroblastoma [61, 
62]. P2X7R are expressed on human malignant glioma and C6 cells [63-65] and high P2X7R 
expression has been correlated with progression-free survival and overall survival [66]. 
P2X7R activation caused release of inflammatory cytokines by macrophages exposed to 
glioma-conditioned medium that was prevented by A-740003 [67]. A P2X7R agonist, 2'(3')-
O-(4-benzoylbenzoyl)-ATP (Bz-ATP), enhanced the temozolomide antitumour effect on 
human cultured glioblastoma stem cells [68]. 
 Autocrine release of ATP and activation of P2X7R influences the metastatic 
migration of human lung cancer H292 and PC-9 cells [69] and in immunodeficient mice, 
migration of transplanted HTB177 and HTB183 lung cancer cells was reduced by A-438079 
[70]. The role of P2X7R in tumour progression is complex and studies show contradictory 
effects of P2X7R activation. For instance, aAn increase in survival of non-small cell lung 
cancer patients with high P2X7R expression was observed [71], although low P2X7R 
expression resulted in greater mRNA (miR-21) expression in the non-small cell lung cancer 
tumours. Thus, the high levels of miR-21 expression in these cancer patients may be a 
consequence of P2X7R downregulation and resultant promotion of tumour progression. 
These results agree with the study by Souza and colleagues [72], which showed that defective 
P2X7R expression following miR-21 activation by a K-Ras mutation, led to reduced 
tumour-killing activity, resulting in a poorer prognosis. P2X7R are expressed in pancreatic 
cancer PancTu-1 Luc cells and antagonists, such as AZ10606120, are likely to be effective 
therapeutic agents [52]. Other antagonists, A-438079 and A-740003, reduced inflammation 
associated with colitis, but increased tumour incidence in a mouse model of colitis-associated 
cancer [73]. In P2X7R-transfected human embryonic kidney cellsHEK293 fibroblasts and 
CT26 colon carcinoma there was enhanced tumorigenesis when the cells were inoculated into 
either immunodeficient and immunocompetent mice, respectively. It was shown that in 
tumours derived from B16 mouse melanoma or ACN human neuroblastoma cell lines, 
tumour growth was inhibited by oxATP [74]. The anthraquinone, emodin, suppressed the 
invasiveness of the highly invasive breast cancer cell line MDA-MB-435s, by antagonizing 
P2X7R [75]. ATP increased [Ca2+]i in breast tumour cells and high concentrations produced 
apoptosis via P2X7R. ATP-mediated activation of the human breast cancer cell line T47D, 
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resulted in an increase in cell migration and the development of metastases, suggesting a 
potential therapeutic role for P2X7R antagonists [76]. P2X7R expression is a prognostic 
indicator for postoperative cancer-specific survival of patients with clear-cell renal cell 
carcinoma [77].  
 Decreased expression of P2X7R is associated with the development of cervical 
cancer. In women, decreased expression of P2X7R is found in endometrial epithelial pre-
cancerous lesions. Activation of P2X7R-dependent apoptosis with BzATP may be a 
chemotherapeutic approach to growth-preventive cell growth modality for of pre-cancerous 
and early cancerous epithelial lesions [78]. Clearly, while ATP and P2X7R activation 
induced apoptosis of tumour cells in some models, in others it accelerated tumour growth. 
 It is known that there are many polymorphisms of the P2X7R [79, 80], which, in 
addition to resulting in a loss of function, may alter the activity of the receptor. Expression of 
non-functional cytolytic P2X7R was found in all pathology specimens of prostate cancer 
examined [81]. P2X7R were not expressed in normal tissues from patients with no evidence 
of cancer, suggesting that the appearance of P2X7R is an early marker of prostate cancer. The 
expression of P2X7R is increased by hypoxia and hypoxia-driven increase in P2X7R 
enhances invasion and migration of tumour cells [82]. Ultraviolet (UV) light has been 
implicated in the genesis of cutaneous cancer, including basal and squamous cell carcinoma 
as well as melanoma. UV-B irradiation destroys P2X7R, by directly killing epithelial cells 
and by reducing P2X7R mRNA by degrading the protein, and may contribute to the 
malignant transformation of keratinocytes [83]. P2X7R were expressed in the necrotic centre 
of nodular basal cell carcinomas and in apoptotic cells in superficial multifocal and 
infiltrative cells. ATP caused apoptosis of cultured A431 human squamous cell carcinoma 
cell line via P2X7R and application of BzATP inhibited the formation of skin papillomas and 
carcinomas in mice [84]. There was increased expression of P2X7R in patients with 
superficial spreading melanomas, which were later shown to be functional, and it was 
suggested that they are a target for melanoma therapy. A low pH environment (like that seen 
in solid tumours) induced ATP release from B16 melanoma cells to increase proliferation via 
P2X7R and oxATP inhibited tumour growth in B16 melanoma-bearing mice [85],. while iIn 
P2X7R KO mice tumour progression of B16 melanoma was accelerated, showing that 
P2X7R are critical to support an antitumor immune response as well as restricting tumour 
growth and metastatic diffusion [86]. γ-Irradiation, which causes growth arrest and death of 
tumour cells, induced P2X7R-dependent ATP release from the B16 melanoma cells. P2X7R 
KO mice were susceptible to bone cancer pain and had an earlier onset of pain-related 
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behaviours. The majority of human osteosarcomas express P2X7R isoforms A and B and the 
expression of either isoform is differently coupled to cell growth and activity [87]. P2X7R 
are involved in cancer-induced bone pain and A839977 was suggested as a useful analgesic 
tool in a rat model of cancer-induced bone pain [88].  
 Activation of P2X7R can either promote cellular survival or induce cytotoxicity and 
depends on the stimulus intensity of ATP to control the ion channel or the P2X7-dependent 
large pore functions. How these two opposite effects are controlled is not fully understood. 
Recently, a feedback loop was described showing that sustained activation of P2X7R results 
in the release of active matrix metalloproteinase 2, which stops ion channel and large pore 
responses in several different cell types, including macrophages and human tumour cells. 
This effect may be an important fine-tuning of P2X7R functions. The authors suggested that 
P2X7R antagonists could be useful as in treating inflammatory diseases and cancers [89]. 
 As the tumour microenvironment contains very high concentrations of ATP, 
adenosine is also present in high concentrations, following enzymatic breakdown of ATP by 
CD39 and CD73. Both ATP and adenosine contribute to immunosuppression or 
immunostimulation of the host, and stimulation of growth or cytotoxicity of the tumour, 
depending on the receptors activated. Thus, targeting specific receptor subtypes produces 
different effects, for example targeting CD73 or A2A receptors reduced immunosuppresion 
and potently inhibited tumour growth [90]. As has been described above, growth of 
experimental tumours is also strongly inhibited by targeting P2X7R of cancer and immune 
cells (see [56]). 
 
 
P2X7R and diseases of the CNS 
The role of P2X7R in diseases related to neuroinflammation and the use of centrally 
penetrant antagonists has been highlighted [1, 11, 14, 17, 91-94]. Blockade of P2X7R may 
serve as a therapeutic target in alleviating the degree of inflammation seen in 
neurodegenerative and neoplastic conditions [95]. Figure 3 is a schematic showing P2X7R-
mediated pathways of common disease mechanisms in CNS disorders of different aetiology. 
P2X7R are upregulated in various disease conditions and stress signals elicit activation, 
which can lead to excitotoxicity, neuroinflammation, neuronal damage, reactive astrogliosis 
or neuroplasticity, contributing to disease pathology (see [92]).  
 
Neurodegenerative diseases 
Fig 3 
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Attention has been directed recently towards the use of P2X7R antagonists for the treatment 
of neurodegenerative diseases, which are often associated with inflammation and damage to 
both neurons and glia [96-99]. P2X7R antagonists were neuroprotective in an animal model 
of Alzheimer’s disease (AD). P2X7R trigger -secretase-dependent processing of the 
amyloid precursor protein to generate β-amyloid peptides, which are present in the amyloid 
plaques in AD. Inhibition of P2X7R in vivo reduces amyloid plaques through glycogen 
synthase kinase 3 and secretases. BBG improved cognition in an animal model of AD and 
inhibited amyloid--induced loss of filopodia and dendrite spines in cultured hippocampal 
neurons [100]. The control of amyloid plaque formation in vivo by P2X7R was reviewed in 
2015 [97] and discussed further in 2017 [101]. It was suggested that P2X7R contribute to 
Parkinson’s disease (PD) pathogenesis through a triple effect on synaptotoxicity, gliosis and 
neurotoxicity, indicating therapeutic potential of P2X7R antagonists for PD [102-104]. BBG 
was neuroprotective in an intranigral lipopolysaccharide (LPS) animal model of PD [104]. 
P2X7R are involved in multiple sclerosis (MS) and in the animal model of MS, experimental 
autoimmune encephalomyelitis (see [105]), where increased expression of P2X7R protein 
was shown in brain homogenates. Genetic variants in P2X7R affect susceptibility to MS 
[106, 107]. Altered P2X7R level and function in mouse models of Huntington’s disease was 
reported and BBG prevented neuronal apoptosis and reduced body weight loss and motor-
coordination deficits [108].   
 Inflammation features in the pathogenesis of amyotrophic lateral sclerosis (ALS). The 
potential of antagonism with BBG for the treatment of ALS was proposed, but it was claimed 
that the treatment was gender-dependent, although this varied in different studies using the 
SOD1-G93A mouse model of ALS: more effective in males [109], more effective in females 
[110] and no difference between the sexes [111]. Similarly, the pathogenesis of ALS was 
shown to differ in different studies. In P2X7R KO-SOD1-G93A mice, onset of the disease 
occurred more rapidly than in wild type (WT) mice, with increased astrogliosis, microgliosis, 
motoneuron loss, induction of the pro-inflammatory markers and activation of mitogen-
activated protein kinase (MAPK) pathways [112]. In a later study by this group using the 
same mouse model of ALS, BBG reduced neuroinflammation at late pre-symptomatic phases 
of the disease, enhanced motor neuron survival and reduced microgliosis in the lumbar spinal 
cord [111]. These differences may be due to the timing of the receptor block, complete 
absence of the receptor in the KO study, as opposed to antagonising the receptor prior to 
symptoms showing in the latter study. Ca2+ abnormalities in ALS exist in both motor neurons 
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and immune cells. Reduction of P2X7R expression on peripheral blood mononuclear cells 
from ALS patients led to calcium dysregulation, a feature of ALS [112]. 
 
Psychiatric disorders 
Activation of microglial P2X7R causes inflammation and brain penetrant P2X7R antagonists 
are being developed since microglial P2X7R are being increasingly recognised as a 
therapeutic target for the treatment of neurological and psychiatric diseases [113]. A review 
on this subject is available [114].  
 There is increased neuronal death via P2X7R and pannexin 1 channels in cultured 
cerebral cortex from prenatal LPS-exposed mice, which suggested a link to an increased risk 
of developing neurological disorders, including schizophrenia, in the offspring (see [115]). 
P2X7R, mediating neuroinflammation via the activity of microglia, may play a role in bipolar 
disorder and offer therapeutic possibilities (see [116]). Antidepressant effects of 
chrysophanol (a natural anthraquinone) via inhibition of P2X7R has been reported in an LPS 
animal model of depression [117]. Similarly, BBG had anti-inflammatory and antidepressant 
effects in mice after LPS administration [118]. Acute restraint stress activates the 
inflammasome via release of ATP and stimulation of P2X7R in a mouse model of stress-
related mood disorders [119] and the antagonist A-804598 was shown to have an impact on 
the neuroimmune and behavioural consequences of stress in a rat model [120]. The P2X7R-
Gln460Arg variant has been associated with mood disorders and co-expression of WT 
P2X7R with the polymorphism variant Gln460Arg transfected into HEK293 human cells was 
found to impair receptor function [121].  
 
Neuroprotection from injury 
There are reviews that discuss the importance of inflammation and the involvement of 
purinergic signalling in the responses to brain injury [8] and of the P2X7R in particular [1, 
14]. P2X7R antagonists are a promising therapeutic tool for the treatment of cerebral 
ischaemia (see [122, 123]). BBG reduced delayed neuronal cell death in the hippocampal 
CA1 region after ischaemia/reperfusion injury and it was found that systemic administration 
of P2X7R antagonists improved recovery after spinal cord injury. The neuroprotective action 
of the P2X7R antagonist, GSK1370319A, acts by inhibiting the assembly of the NLRP3 
inflammasome in glial cells [124, 125]. ATP enhanced radiation-induced brain injury through 
microglial activation via P2X7R-mediated release of inflammatory mediators, such as 
cyclooxygenase-2, tumour necrosis factor-α (TNF-α) and IL-6, and P2X7R antagonists were 
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suggested as a potential strategy for the treatment of patients with radiation-induced brain 
injury [126]. Activation of P2X7R in the hippocampus following traumatic brain injury was 
thought to imply cognitive impairment in rats [127], while A-438079 provided 
neuroprotection toward neurological disorders, including stroke, traumatic brain injury and 
subarachnoid haemorrhage, as well as preserving blood brain barrier integrity [128].  
 Recent papers have recognised a role for P2X7R antagonists for the treatment of 
epilepsy, including drug-resistant epilepsy [8, 129, 130]. P2X7R antagonism produced lasting 
reduction in the development of spontaneous seizures and inhibited glial inflammatory 
responses in mouse models of experimental temporal lobe epilepsy [131] and 
pentylenetetrazol-induced seizures [132]. However, in pilocarpine-induced status epilepticus 
in mice, blockade of central P2X7R increased the number of seizures and their severity [133]. 
P2X7R are considered as a target for the treatment of hypoxic/ischaemic encephalopathy and 
other causes of neonatal seizures since in A-438079-treated mice, seizure number, EEG 
power and spiking during hypoxia, as well as molecular markers of inflammation and 
microglia were reduced [130]. 
 
Cardiovascular diseases 
The long non-coding short interfering RNA (silncRNA), NONRATT021972, targeted using a 
small interfering RNA (siRNA), decreased the upregulation of P2X7R in the superior 
cervical ganglion and improved cardiac function after myocardial ischaemia in rats [134]. 
Myocardial ischaemic injury facilitated sympathoexcitatory action via P2X7R and it was 
suggested that P2X7R antagonists may be useful for the treatment of coronary heart disease 
as expression of P2X7R is increased during coronary ischaemia-reperfusion [135]. Microglial 
P2X7R in the rat hypothalamic paraventricular nuclei regulate the sympathoexcitatory 
responses in acute myocardial infarction and gene knockdown of P2X7R with P2X7-siRNA, 
or inhibition with BBG, reduced mRNA and protein expression of IL-1β and TNF-α [136]. 
P2X7R involvement in dilated cardiomyopathy has been reported in P2X7R KO mice [137]. 
A-740003 reduced experimental autoimmune myocarditis in a mouse model, suggesting a 
treatment for clinical myocarditis [138]. P2X7R in the kidney play a role in hypertension and 
it has been suggested that P2X7R antagonists may have promise as clinical antihypertensive 
agents. In atherosclerotic mice, P2X7R are over-expressed whereas P2X7R KO mice were 
found to have less plaque formation and decreased leukocyte recruitment following ATP-
Stimulation [139]. P2X7R are pro-thrombotic and genetic KO of the P2X7R gene is 
protective in a mouse model of carotid artery thrombosis. Vasomotor dysfunction was caused 
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by sub-failure overstretch injury in rat abdominal aorta via activation of P2X7R and this 
suggested that the use of antagonists for the treatment of vascular stretch injury in humans 
may be beneficial [140]. 
 
Diseases of the airways 
Inflammation occurs in most diseases of the airways, including asthma, chronic obstructive 
pulmonary disease, cystic fibrosis, dyspnea, allergy, infection and injury. P2X7R are a target 
for therapeutic intervention in lung hypersensitivity reactions associated with chronic 
inflammatory responses. Extracellular ATP was recognised as a danger signal activating 
P2X7R in lung inflammation and fibrosis and P2X7R antagonists were proposed as a novel 
therapeutic approach in humans to control IL-1β production and fibrosis in lung injury [141] 
as well as in silicosis, an occupational lung disease, following a study in a mouse model 
[142]. Attenuated P2X7R function gives protection from asthma and is age-related, being 
most effective in young boys. P2X7R have also been implicated in the pathophysiology of 
allergy-induced lung inflammation. Targeting P2X7R on haematopoietic cells, namely 
dendritic cells or eosinophils, may be a therapeutic approach for the treatment of allergic 
asthma. The anti-allergic antihistamine, oxatomide, is claimed to also act as a P2X7R 
antagonist in N18TG2 and J774 cells [13]. BBG prevented neurogenic pulmonary oedema 
after subarachnoid haemorrhage in rats by attenuating inflammation [143]. Cigarette smoke 
activates P2X7R signalling, which appears to be involved in the pathogenesis of emphysema, 
and induces ATP and inflammatory cytokine release from neutrophils via P2X7R activation 
[144]. Polymorphisms of the P2X7R gene are associated with the risk and prognosis of 
human tuberculosis [145]. Data was presented to support the view that P2X7R antagonists 
should be used to treat the aggressive forms of tuberculosis [146]. ATP, released by activated 
macrophages and damaged cells, modulates lung inflammation in pneumonia in cattle. Both 
epithelial cells and pulmonary microvascular endothelial cells expressed mRNA for P2X7R, 
as did alveolar macrophages, which, when stimulated, activate the proinflammatory IL-1 to 
IL-5 cytokine cascade. P2X7R are involved in the pathophysiology of LPS-induced lung 
injury [147] and there is up-regulation of pulmonary P2X7R in both acute and chronic lung 
injury in mice where P2X7R deletion was shown to be lung protective [148]. Pulmonary 
neutrophils are the initial inflammatory cells to be recruited during lung injury and are crucial 
for innate immunity. In contrast, pathological recruitment of neutrophils results in lung injury 
and P2X7R antagonists were shown to reduce neutrophil infiltration and proinflammatory 
cytokine levels [15].  
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Gut disorders 
Extracellular nucleotides and their receptors are involved in the pathogenesis of inflammatory 
bowel disease (IBD), which includes two main forms, namely ulcerative colitis (UC) and 
Crohn’s disease (CD). P2X7R are involved in colonic motor dysfunction associated with 
bowel inflammation in rats [149] and are over-expressed in gut mucosa of patients with CD 
[150]. P2X7R KO mice were protected against gut inflammation, while in WT mice, ATP via 
P2X7R triggers the death of mucosal regulatory T cells [151]. Oestrogen receptor β 
activation may play a therapeutic role in IBD by down-regulation of P2X7R [152]. Reviews 
discussing the role of P2X7R in IBD are available [153, 154]. UC differentially affects 
P2X7R-expressing enteric neurons based on their chemical codes [155]. In a later paper, it 
was shown that trinitrobenzene sulfonic acid-induced UC in rats affected secretory and 
vasodilatory neurons, enteric sensory neurons and enteric glia of the submucosal plexus 
expressing P2X7R [156]. ATP mediates inflammatory responses in dextran sulfate sodium-
induced UC in mice via P2X7R signalling and A-438079 down-regulated the production of 
proinflammatory cytokines and attenuated the colitis [157]. There is increased expression of 
P2X7R in the inflamed mucosa in CD in humans and animal models, suggesting that P2X7R 
may be a target for treatment of CD [151, 158, 159]. Purinergic signalling is involved in 
gastrointestinal motility disorders, such as diarrhoea and constipation. P2X7R activity was 
enhanced in enteric glia that were isolated from mice with long-term morphine treatment, 
which can result in colonic inflammation [160]. 
 
Diseases of the kidneys 
Increased expression of P2X7R in renal hypertension, polycystic kidney disease (PKD) and 
glomerulonephritis is opening up novel purinergic possibilities for the treatment of kidney 
failure (see [161, 162]). A-438079 protected against ischaemic acute kidney injury in mice 
[163]. P2X7R are expressed in collecting duct cysts in the cpk/cpk mouse model of 
congenital PKD, and mRNA and protein increased as the disease developed. ATP inhibits 
renal cyst growth, via P2X7R and oxATP and A-438079 reduced cyst formation via MAPK-
dependent pathways in a zebrafish model of PKD [164]. P2X7R expression has been 
demonstrated in both experimental and human glomerulonephritis, which suggests that 
P2X7R antagonists may have therapeutic potential [165]. P2X7R-deficiency attenuated renal 
injury in experimental glomerulonephritis in mice. BBG attenuated nephritis by inhibiting 
inflammasome activation in a mouse model of lupus nephritis [166]. There is predominant 
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P2X7R control of glomerular haemodynamics in angiotensin-II hypertension [167]. While 
the P2X7R is are only weakly expressed in healthy kidney, they areit is significantly 
upregulated in hypertension [168], antagonism of which would reduce interstitial 
inflammation, prevent interstitial cell death and improve blood pressure control. P2X7R 
antagonism prevented the development of salt-sensitive hypertension and renal injury in Dahl 
salt-sensitive rats [169]. P2X7R expression was increased in human kidneys with type 2 
diabetes and activation of P2X7R evoked renal inflammation and injury in the high-fat diet 
model of metabolic syndrome, suggesting that P2X7R antagonists might be useful 
therapeutically for diabetic nephropathy [170]. P2X7R activation contributes to the high 
prevalence of kidney disease found in diabetics [162].  
 
Diseases of the lower urinary tract  
Localized inhibition of P2X7R at the spinal cord inflammatory injury site in a rat model, 
reduced microglia numbers and improved neurogenic bladder dysfunction [171]. P2X7R, 
expressed by macrophages and neutrophils in the bladder submucosa, are increased in 
cyclophosphamide-induced haemorrhagic cystitis in mice and treatment with A-438079 or 
genetic ablation of this receptor reduced the tissue levels of IL-1β and TNF-α and reduced 
nociceptive behaviour [172]. It was shown that 7 days after unilateral ureteral obstruction in 
WT mice there was increased expression of P2X7R associated with inflammation and 
fibrogenic responses in the cortex [173]. It was suggested that there is a potential role for 
P2X7R antagonists to prevent renal interstitial fibrosis [174].  
 
Diseases of the liver 
In mouse models of acetaminophen (APAP)-induced inflammation, liver injury after 
overdose involved P2X7R activation [175] resulting in hepatic caspase-1 and migration of 
neutrophils into the liver, suggesting that ATP may play a pivotal role in the development of 
inflammasomes after APAP overdose [176]. A-438079 was reported to be protective against 
APAP-induced liver injury, by an effect on metabolic activation and cell death pathways, 
rather than on involvement of the inflammasomes [177]. Blockade of the P2X7R-NLRP3 
inflammasome axis is a potential therapeutic target for liver fibrosis [178]. In mice with 
induced autoimmune hepatitis, activation of P2X7R on natural killer T cells was shown to 
inhibit naive, but stimulate activated cells, resulting in suppression or stimulation of the 
autoimmune hepatitis [179]. P2X7R-mediated responses participate in infection of human 
hepatocytes by hepatitis delta virus and hepatitis B virus. P2X7R mediate leptin-induced 
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GLUT4 function in mice stellate cells in non-alcoholic steatohepatitis [180]. P2X7R may be a 
major component of the purinergic signalling complex in hepatitis C virus-induced liver 
pathogenesis [33]. 
 
Skin diseases 
A valuable review discusses the involvement of P2X7R in skin biology and their role in 
inflammatory skin disorders, including irritant and chronic dermatitis, psoriasis, cancer, graft-
versus-host disease, as well as wound healing and transplantation [181]. Inflammation of the 
skin is associated with release of ATP, increase in expression of purinoceptors, particularly 
the P2X7R, and subsequent release of proinflammatory cytokines from immune cells [182]. 
P2X7R antagonists reduce skin inflammation. In psoriasis high P2X7R expression, confined 
to the cell membrane of the basal layer of the epidermis, plays a role in shaping the 
inflammatory microenvironment [183], leading to differentiation of Th17 lymphocytes, 
which are involved in the pathogenesis and potential treatment of psoriasis [184]. Systemic 
sclerosis fibroblasts express mRNA for several P2R subtypes, including P2X7R, suggesting a 
potential therapeutic role for P2X7R antagonists in systemic sclerosis patients. In the initial 
phase of wound healing there is acute inflammation. P2X7R on immune cells also mediate 
killing of intracellular pathogens by inducing apoptosis of host macrophages, chemo-
attraction and cell adhesion. P2X7R immunoreactivity was associated with hyperkeratotic 
areas of the stratum corneum and in nuclei of koilocytes in the suprabasal layers of warts 
[185]. The nuclei that were positive for P2X7R were shrunken, showing much more intense 
P2X7R staining. The presence of P2X7R in the nucleus of human papillomavirus-infected 
cells indicates disruption of the cellular machinery. P2X7R agonists may be used to trigger 
apoptosis in these virally infected cells. Sensitization to contact allergens requires activation 
of the immune system by endogenous danger signals. Mice lacking P2X7R are resistant to 
contact hypersensitivity. P2X7R-deficient dendritic cells fail to induce sensitization to 
contact allergens and do not release IL-1β in response to ATP, suggesting that the P2X7R 
areis crucial for extracellular ATP release in skin in response to contact allergens [186]. 
Interference with P2X7R signalling may be a promising strategy for the prevention of allergic 
contact dermatitis. There is a pathogenic role for keratinocyte-derived ATP in irritant 
dermatitis. The necrosis produced by the chemical irritant croton oil was prevented in mice 
by pre-treatment with A-438079 [187].  
 
Musculoskeletal diseases 
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P2X7R proteins were upregulated on dystrophic myoblasts of mdx mice (a mouse model of 
Duchenne muscular dystrophy) and it was suggested that antagonists to these receptors may 
be of potential therapeutic benefit [188] as treatment with BBG or oxATP slowed the 
progression of disease in the mouse model [189]. The P2X7R has received the most attention 
in relation to the treatment of osteoporosis [190]. P2X7R plays an important role in both 
cortical and cancellous bone mass augmentation. They were shown to mediate stimulation of 
periosteal and cancellous bone formation and inhibition of cancellous bone resorption during 
growth [190]. The P2X7R is polymorphic and sSingle nucleotide polymorphisms (SNPs) of 
the P2X7 gene are associated with fracture risk, decrease in bone mineral density and 
osteoporosis [191]. P2X7R are also involved in the chain of events leading to the formation 
of human osteoclasts, and P2X7R antagonists may have therapeutic roles in bone diseases 
with an increase in osteoclast number, such as Paget’s disease [192]. P2X7R antagonists may 
be useful for the management of osteoporosis and with disorders of remodelling, where there 
is reduced bone mass [193]. Different polymorphic variants of the P2X7R are associated with 
high or reduced periprosthetic osteolysis in the long term complication of total hip 
arthroplasty due to osteoarthritis [194]. Cross-talk between P2X7R and Wnt/β-catenin 
pathways may modulate osteoblast activity in response to mechanical loading [195]. 
Treatment with AZD9056, a selective P2X7R antagonist, produced pain-relieving and anti-
inflammatory effects in rats with osteoarthritis [196]. ATP, via P2X7R, induced higher levels 
of IL-1β in blood samples from rheumatoid arthritis (RA) patients compared to controls. It 
was suggested that mononuclear cells from these patients were more sensitive to ATP 
stimulation, perhaps due to genetic polymorphism in the P2X7R gene [197]. P2X7R play a 
role in the pathogenesis of RA and systemic lupus erythematosus. Human rheumatoid 
synoviocytes express P2X7R mRNA and protein. Animal models of arthritis have provided 
evidence for an in vivo role for the P2X7R in the progression of inflammatory disease. In 
P2X7R KO mice there was a reduced incidence and severity of anti-collagen-induced arthritis 
symptoms, therefore targeting the P2X7R may be a promising treatment for RA [198]. Block 
of P2X7R signalling in the collagen-induced arthritis animal model of RA inhibited 
peripheral inflammatory tissue destruction. P2X7R antagonists have been explored for the 
treatment of inflammatory pain in joints [199]. Charcot-Marie-Tooth 1A is a demyelinating 
hereditary neuropathy and A-438079 improved the clinical phenotype of the disease in a rat 
model and was recommended for its treatment [200]. A review was published about P2X7R 
antagonists in rodent models of musculoskeletal and other disorders [201].  
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P2X7R in inflammation, infection and immunity 
Extracellular ATP is an endogenous danger signal that activates inflammatory responses in 
immune cells. The role of P2X7R in infectious inflammatory diseases has been reviewed [8, 
18, 19]. P2X7R are needed for the development of the inflammatory response associated with 
sepsis in mice [20, 21] and BBG was shown to ameliorate sepsis-induced brain damage [22]. 
Also in mice, P2X7R downstream of caspase-11 play a critical role for pyroptosis and 
susceptibility to sepsis induced by the non-canonical inflammasome [23]. 
 The use of P2X7R agonists in conjunction with low molecular weight anti-bacterial 
medicines has been proposed for the treatment of multi-drug-resistant tuberculosis [24]. 
P2X7R antagonists are potential tools for the treatment of Clostridium perfringens type C 
[25] and Porphyromonas gingivalis [26] infections and P2X7 activation was shown to be 
protective during severe Escherichia coli infection in mice [27] and host protection from 
Bacillus anthracis [28]. Over-expression of the ectonucleotidase, CD39, in mouse airways 
promotes bacteria-induced inflammation, mediated largely by P2X7R. The role of P2X7R 
and ectonucleotidases in infectious inflammatory diseases has been reviewed [19]. 
 Evidence was presented to show that the mouse P2X7R is involved in containing the 
parasitic protozoan Toxoplasma gondii spread in vivo, by stimulating inflammation [29]. The 
dysfunction of P2X7R is likely to contribute to morbidity due to human schistosomiasis, a 
chronic inflammatory disease [30]. P2X7R-deficient mice were more susceptible to 
Leishmania amazonensis infection than WT mice, suggesting that P2X7R play a key role in 
parasite control by regulating T effector cells and inflammation [31].  
 P2X7R activation regulates inflammatory responses during acute viral infection in 
mice [32]. Upregulated expression of P2X7R on peripheral blood mononuclear cells provides 
antiviral immunity in patients against hepatitis C virus [33], while activation of P2X7R 
participates in the exacerbated immune response that occurs during influenza virus infection 
in mice [34]. P2X7R play a role in control of Dengue virus-2 infection and KN62 appeared to 
have antiviral and anti-inflammatory actions in infected human monocytes [35]. Purinergic 
receptors, particularly P2X7, have been identified as key mediators of human 
immunodeficiency virus-1 (HIV-1) infection and inflammation [36] and ATP induces rapid 
release of HIV-1 from virus containing compartments of human macrophages [37]. In HIV-1 
infection, abnormalities in neuron-glia interactions result in neuronal damage. HIV-1 Tat-
induces neuronal apoptosis and augments the expression of P2X7R in astrocytes. OxATP, A-
438079 and BBG attenuated Tat-mediated neurotoxicity and may be novel tools for 
therapeutic management of neuroAIDS [38].  
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 A valuable review discusses the role of purinergic signalling in autoimmunity and 
highlights a role for P2X7R in systemic lupus erythematosus [39]. P2X7R activation deleted 
intestinal T cells by apoptosis and suppressed T-cell-induced colitis in mice [40]. P2X7R are 
expressed on peripheral lymphocytes and may influence the immune profile from patients 
with the indeterminate form of Chagas disease [41].  
P2X7R and diabetes 
Type 1 and type 2 diabetes are inflammatory diseases. P2X7R KO in mice prevents 
streptozotocin (STZ)-induced type 1 diabetes and the levels of proinflammatory mediators 
(IL-1β, interferonIFN-γ and nitric oxide) did not increase [202]. P2X7R-pannexin 1 channels 
impair bone mechanosignalling in osteocytes associated with type 1 diabetes that affects 
osteoblast function and maintenance of bone health [203]. In STZ-induced diabetic animals, 
P2X7R located on glucagon-containing  cells in pancreatic islets, increase and they migrate 
centrally to take the place of the missing insulin-containing  cells [204]. OxATP in mice has 
been proposed as a therapeutic tool to cause immunosuppression and tolerance induction in 
pancreatic islet transplantation [205, 206]. LncRNA NONRATT021972 siRNA decreases the 
expression of P2X7 mRNA and protein in DRG, thereby reducing mechanical and thermal 
hyperalgesia in type 2 diabetic rats [207]. ATP concentrations and P2X7R expression was 
increased , shown to be upregulated in glial cells in rats with painful diabetic neuropathy 
[208]. Diabetic sympathetic neuropathy in type 2 diabetic rats was improved by reducing the 
expression of P2X7R with lncRNAuc.48+ siRNA in superior cervical ganglia [209]. 
Different P2X7R polymorphisms are associated with pain sensitivity formore or less severe 
diabetic neuropathic pain patients, such that patients with the gain-of-function SNP report 
more severe pain, where as those with a loss-of-function SNP report less painscores when the 
pain was tested and scored [210]. P2X7R antagonists may be a useful coadjuvant treatment to 
delay the progression of diabetic nephropathy [211].  
 
Conclusions 
It is clear from the recent literature that P2X7R antagonists are potential effective therapeutic 
agents for the treatment of inflammatory diseases and cancer. There is a problem, however, 
concerning the many polymorphic forms of the human P2X7R, as care must be taken in 
identifying those patients that would most benefit by the available antagonists, as different 
antagonists are not always effective agents at some of the polymorphic types (see [212]). 
There is an explosion of interest in developing centrally penetrant P2X7R antagonists and 
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their therapeutic explorations in clinical trials [213-215]. The relation between inflammation 
elicited by P2X7R activation and the immune system needs further exploration. Apart from 
the potential of the therapeutic use of P2X7R antagonists for CNS disorders (including 
neurodegenerative diseases, brain injury, psychiatric diseases, epilepsy and neuropathic pain), 
there is increasing recognition of their use for the treatment of diseases of the heart, lung, gut, 
kidney, liver and bladder. The reasons for dual roles of P2X7R mediating cell proliferation 
and apoptotic cell death needs further investigation of the mechanisms involved. 
 The purinergic signalling field is now well established and much known about the 
physiological roles played by this system. The emphasis now is on the pathophysiology and 
therapeutic potential of purinergic signalling (see [216, 217]). For example, clopidogrel (trade 
name Plavix) and ticagrelor (trade name Brilique) are P2Y12 receptor antagonists that inhibit 
platelet aggregation and are widely used for the treatment of thrombosis and stroke (see 
[218]). 
 Characterisation of the P2Y class (see [219]) made it possible to identify specific 
agonists of the P2Y2 receptor, which evokes mucus secretion. A new, long-lasting agonist, 
diquafasol (Diquas), has been developed by Inspire Pharmaceuticals [220]. Diquas was 
launched by Santen in Japan in 2010, with Inspire Pharmaceuticals.  
 Through the cloning of the P2X3 ion channel receptor located on nociceptive sensory 
nerves [221] and later the discovery of the involvement of these channels in signalling pain 
(see [222]), a new target for pain relief is receiving attention from the pharmaceutical 
industry. Roche and, more recently, Afferent Pharmaceuticals have developed AF-219, a 
specific P2X3 antagonist, which is a promising new analgesic, orally bioavailable and stable 
in vivo [223]. AF-219 is currently in Phase 2 clinical trials for the treatment of three painful 
disorders: osteoarthritis; interstitial cystitis/bladder pain syndrome; and idiopathic chronic 
cough. Four Phase 1 studies of AF-219 have demonstrated that the compound is safe and well 
tolerated and the Phase 2 clinical trials were completed earlier this year [224]. Antagonism of 
P2X3 receptors on primary afferent neurons is a novel analgesic approach that has been 
pursued by leading pharmaceutical companies for the last 15 years. Over 600 patents are 
currently held which relate to the P2X3 receptor and pain 
(https://patentscope.wipo.int/search/en/result.jsf). There are currently investigations into the 
potential therapeutic use of purinergic compounds for osteoporosis, irritable bowel syndrome, 
atherosclerosis, kidney failure and cancer.  
 Since P2X7R-mediated inflammation is associated with a wide range of diseases, 
medicinal chemists in research institutes, universities and drug companies are optimistic that 
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P2X7R antagonists are promising tools for the treatment of inflammatory diseases and more 
than 70 patents have been filed in the last few years by Glaxo, AstraZeneca, Roche, Janssen 
and Abbott, to name a few. For instance, Abbot filed a patent from the use of A-438079 in 
disease models of affective disorders and status epilepticus, while Abbott filed for triazole-
based compounds for the CNS disorders and as a therapeutic strategy to treat spinal cord 
injury and the University Hospitals of Cleveland claimed in vitro and in vivo effects of 
P2X7R antagonists in epithelial cancer and papilloma (see [215]). 
 As mentioned above, a major challenge is to understand which polymorphic 
variations of the P2X7R have relevance to which disease and to fit patients with different 
polymorphisms to the P2X7R antagonist that would have the greatest efficacy for that 
variant. For example, the responses of human leukocytes to GSK1370319A were 
significantly altered, directly related to the SNP genotype, there being a 6.7-fold difference in 
the inhibition of ATP-stimulated IL-1βb release by GSK1370319A between individuals with 
the homozygous gain- and loss-of-function genotypes [225]. A correlation was found 
between some gain-of-function and loss-of-function P2X7R SNPs, transfected into HEK-293 
cells, and the expression of the channel protein. A change in both channel and pore function 
was described for the mutant P2X7R in parallel to the protein levels, although the agonist and 
antagonist sensitivity was not altered. The presence of the gain-of-function SNP (rs208294 
(His155Tyr) and rs1718119 (Ala348Thr)) in female patients with diabetic peripheral 
neuropathic pain was associated with higher pain intensity scores [210]. Recently, mutations 
and molecular modelling studies have identified an allosteric binding site forming at the 
subunit interface at the apex of the receptor, distinct from the ATP-binding pocket, that 
regulates access of antagonists, such as AZ10606120, to the allosteric site. This allosteric 
pocket may provide novel targets for P2X7R drug development [226, 227], although the 
effect of polymorphic variations on the allosteric site have not been elucidated yet.  
 Also, more needs to be discovered about the relation of inflammatory diseases to the 
immune system where lymphocytes, macrophages, monocytes, neutrophils, basophils, 
dendritic cells, eosinophils and mast cells all express P2X7R (see [6]). 
 It seems likely that a breakthrough will occur about the use of P2X7R antagonists for 
a variety of diseases in the future, including, in particular, neurodegenerative diseases and 
cancer and the description of the crystal structure of mammalian P2X7R can only help in this 
endeavour [227, 228].  
 In addition to the therapeutic potential of P2X7R antagonists, P2X3R antagonists look 
extremely promising for the treatment of chronic cough, visceral pain, bladder disorders and 
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hypertension. Exploration of the use of purinergic drugs for the treatment of obesity is also 
well worth pursuing.         
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Figure Legends 
 
Figure 1 
Cell type-specific schema of ATP release and action. ATP (red triangles) can be released 
from the cell cytosol to the extracellular space (dashed red line) via pannexin 1 (Panx1) 
channels or connexin 43 (Cx43) hemichannels (pictured). Once in the extracellular space, this 
ATP acts as a paracrine transmitter, as can ATP released from nearby cells that are dead or 
dying (not shown). Extracellular ATP can activate P2 receptors, such as P2X7 receptors 
(P2X7R) (pictured) that depolarises the target cell, but also activates an inflammatory 
response in immune cells (dashed gray line) with subsequent release of cytokines such as 
interleukin (IL)-1β that can act back at Panx1 and Cx43 to modulate their function (dashed 
gray lines). Activation of P2X7R also mediates the T-cell responses (e.g., Ca2+ entry, IL-2 
synthesis) and macrophage migration (not shown). (Reproduced from [153], with permission 
from Frontiers Media S.A. (via Open Access).) 
 
Figure 2 
Altered regulation of calcium channels in brain tumours is part of neoplastic transformation. 
In the brain, the transformation of a normal cell into a tumour cell might be related to 
Ca2+ oscillations, and the homeostasis misbalance can define the malignant phenotype, which 
includes uncontrolled proliferation, enhanced migration and invasion, and abnormal cell 
death. The activation of P2X7 receptors (P2X7R) leads to extracellular signal-regulated 
protein kinases 1 and 2 (ERK1/2), phosphatidylinositol 3-kinase (PI3K), and mitogen-
activated protein kinase 1/2 (MEK1/2) activation. High P2X7R functionality and pore 
activity are linked to apoptosis/necrosis in glioma cells and better progression-free survival. 
(Reproduced from [54], with permission from the American Society for Pharmacology and 
Experimental Therapeutics.) 
 
Figure 3 
Common disease mechanism by P2X7 receptor (P2X7R)-mediated pathways in central 
nervous system (CNS) disorders of different etiology. P2X7Rs are expressed on nerve 
terminals, astrocytes, and microglia, and they are upregulated in various disease conditions. 
Stress signals, such as hypoxia/ischemia (metabolic limitations), mechanical injury, and 
bacterial or chemical toxins elicit the endogenous activation of P2X7R and leads to a self-
amplifying ATP release and to further activation of P2X7R on neighbouring cells. Following 
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the influx of Ca2+ through the receptor ion channel complex, P2X7R activation (i) releases 
glutamate from nerve terminals and astrocytes by both exocytotic and non-exocytotic 
mechanisms, which may give rise excitotoxicity; (ii) leads to the posttranslational processing 
of pro-interleukin-1β (pro- IL-1β) to the leaderless, mature IL-1β and to its further release by 
the NLRP3 inflammasome and that of other cytokines, which contribute to 
neuroinflammation; (iii) enhance reactive oxygen species (ROS) production and thereby 
aggravate protein misfolding and neuronal damage; (iv) leads directly or indirectly to cell 
death and the following reactive astrogliosis; and (v) directly or indirectly downregulates the 
production of brain-derived neurotrophic factor (BDNF) and the subsequent neuroplasticity. 
These key mechanisms could be manifested and contribute to disease pathology in 
Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), status 
epilepticus (SE), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, pain, 
and mood disorders in different forms and proportion, depending on the etiology. 
Abbreviations: GLU, glutamate, ROS, reactive oxygen species. (Reproduced from [92], with 
permission from Elsevier.) 
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